Methods for treatment of cancer
First Claim
1. A method of treating a hematological cancer in a human patient, the method comprising administering to the human patient a pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the cells of the population include cells that comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain comprising the amino acid sequence of SEQ ID NO:
- 20, a CD8α
hinge domain, a CD8α
transmembrane domain, a 4-1BB costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cells are T cells of a human patient having a hematological cancer.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
143 Citations
30 Claims
-
1. A method of treating a hematological cancer in a human patient, the method comprising administering to the human patient a pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the cells of the population include cells that comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain comprising the amino acid sequence of SEQ ID NO:
- 20, a CD8α
hinge domain, a CD8α
transmembrane domain, a 4-1BB costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cells are T cells of a human patient having a hematological cancer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
- 20, a CD8α
-
28. A method of treating lymphoma in a human patient, the method comprising administering to the human patient a pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the cells of the population include cells that comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain comprising the amino acid sequence of SEQ ID NO:
- 20, a CD8α
hinge domain comprising the amino acid sequence of SEQ ID NO;
21, a CD8α
transmembrane domain comprising the amino acid sequence of SEQ ID NO;
22, a 4-1 BB costimulatory signaling region comprising the amino acid sequence of SEQ ID NO;
23, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO;
24, wherein the T cells are T cells of a human patient having lymphoma. - View Dependent Claims (29)
- 20, a CD8α
-
30. A method of treating multiple myeloma in a human patient, the method comprising administering to the human patient a pharmaceutical composition comprising an antitumor effective amount of a population of human T cells, wherein the cells of the population include cells that comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain comprising the amino acid sequence of SEQ ID NO:
- 20, a CD8α
hinge domain comprising the amino acid sequence of SEQ ID NO;
21, a CD8α
transmembrane domain comprising the amino acid sequence of SEQ ID NO;
22, a 4-1 BB costimulatory signaling region comprising the amino acid sequence of SEQ ID NO;
23, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO;
24, wherein the T cells are T cells of a human patient having multiple myeloma.
- 20, a CD8α
Specification